Renal Cancers Completed Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Renal Cancer / Kidney Cancer / Renal malignant neoplasm / Renal neoplasms malignant / Cancer of Kidney

IndicationStatusPhase
DBCOND0044624 (Renal Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00853021Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the KidneyTreatment
NCT00782275Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell CarcinomaTreatment
NCT00113217Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell CarcinomaTreatment
NCT00193154OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell CarcinomaTreatment
NCT00323739Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal CarcinomaTreatment
NCT00455975High-dose Bevacizumab in Advanced Renal Carcinoma PatientsTreatment
NCT00496587Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell CarcinomaTreatment